Skip to content Skip to footer
Subscribe Now
NEWS

Insilico Medicine and SK Biopharmaceuticals Sign AI-Driven Drug Discovery Deal Worth Up to $2.5B for Neuroimmune Disorders

Shots: Insilico Medicine and SK Biopharmaceuticals entered a research and development collaboration to discover AI-enabled therapies for neuroimmune disorders of the central nervous system (CNS), including neuroinflammatory, neurodegenerative, and rare neurological diseases Under the agreement, Insilico will utilize its proprietary Pharma.AI platform, covering target validation, generative chemistry, and molecule optimization, alongside its preclinical drug discovery…
June 22, 2026

Read more

NEWS

MoonLake Reports Positive Week 52 P-III (VELA) Data for Sonelokimab in Hidradenitis Suppurativa (HS)

Shots: MoonLake Immunotherapeutics reported positive 52 Wks. (n=396) results from the P-III (VELA-1) and (VELA-2) studies, demonstrating durable efficacy of sonelokimab in adults with moderate-to-severe HS At Week 52, 67.2% of pts. achieved HiSCR75, 33.1% achieved HiSCR100, and 26.0% reached inflammatory remission (IHS4-100). Sonelokimab also showed substantial improvements in quality of life and pain reduction,…
June 22, 2026

Read more

NEWS

Danone to Acquire MADE Group to Strengthen Healthy Nutrition Portfolio in APAC

Shots: Danone entered definitive agreements to acquire MADE Group and the remaining 49% stake in its Australian fresh dairy joint venture with Saputo Dairy Australia, expanding its footprint in the APAC healthy nutrition market MADE’s portfolio includes health-focused products such as high-protein ready-to-drink beverages, gut-health yoghurts, and coconut-based products. The Australia-based company generated sales of…
June 22, 2026

Read more

TOP 20

Top 20 Nutraceutical Companies of 2026 

Shots:  The global nutraceutical market is advancing through preventive healthcare, personalized nutrition, probiotics, sports nutrition, and healthy ageing solutions. In 2025, Nestlé led the industry with $18.1B in nutraceutical revenue, followed by Danone ($10.91B) and Abbott Nutrition ($8.45B), reflecting strong demand for science-backed wellness products  Valued at $636.2B in 2025, the global nutraceutical market is…
June 12, 2026

Read more

TOP 20

Top 20 Diagnostics Companies of 2026

Shots:  The global diagnostics market is rapidly evolving through AI-powered imaging, molecular testing, precision medicine, and digital pathology solutions. In 2025, Siemens Healthineers led the industry with $20.54B in diagnostics revenue, followed by Roche at $17.52B and GE HealthCare at $17.49B, reflecting the growing adoption of advanced imaging, lab automation, and AI-driven diagnostics across global…
May 29, 2026

Read more

TOP 20

Top 20 Medical Device Companies of 2026 

Top 20 Medical Device Companies of 2026  Shots:  The global medical devices market is entering a new era of transformation, powered by AI-driven diagnostics, robotic surgery, cardiovascular breakthroughs, and minimally invasive innovation. Valued at $572.31B in 2025, the market is racing toward the $1T milestone by 2034. In FY2025, Medtronic dominated with $35.48B in revenue,…
May 15, 2026

Read more

TOP 20

PharmaShots Awards 2026: Celebrating the Titans Transforming the Future of Global Healthcare 

Shots:  PharmaShots Awards 2026 celebrates the industry’s most influential innovators across biopharma, MedTech, diagnostics, generics, nutraceuticals, animal health, digital health, and AI-driven drug discovery spotlighting organizations redefining the future of global healthcare.  From Eli Lilly, Pfizer, and AbbVie to Medtronic, Roche, Siemens Healthineers, and XtalPi, this year’s awardees exemplify scientific excellence, breakthrough innovation, and a relentless commitment to…
May 2, 2026

Read more

Top 20 Biopharma Deal Terminations of 2025
TOP 20

Top 20 Biopharma Deal Terminations of 2025 

Shots:  Biopharma dealmaking in 2025 continued to face significant headwinds, with collaborations frequently collapsing due to strategic reprioritization, fierce competitive pressures, unfavorable clinical readouts, and failure to meet key closing conditions highlighting the inherent uncertainty and capital risk embedded in innovation-driven partnerships   The year underscored a clear dominance of R&D-focused collaborations and licensing agreements,…
April 24, 2026

Read more

NEWS Uncategorized

Pheast Therapeutics Reports Early P-Ia Data for PHST001 at AACR 2026

Shots: Pheast Therapeutics presented initial P-Ia data for PHST001 at AACR Annual Meeting 2026, demonstrating target engagement, innate immune activation, and early clinical activity PHST001 (anti-CD24 macrophage checkpoint inhibitor) was generally well tolerated, across dose-escalation cohorts and early signals of clinical activity were observed incl. tumor shrinkage and disease stabilization Preclinical data showed enhanced tumor…
April 20, 2026

Read more

Novo-Nordisk
NEWS

Novo Nordisk Reports Positive P-III (HIBISCUS) Study Data for Etavopivat in Sickle Cell Disease

Shots: Novo Nordisk reported that etavopivat met both co-1EPs in the P-III (HIBISCUS) study, reducing vaso-occlusive crises (VOCs) and improving haemoglobin response in sickle cell disease The study (n=385, ≥12yrs) evaluated Etavopivat (400mg) vs PBO demonstarting reduced VOCs rates by 27% and delayed time to first VOC (~38.4 vs 20.9 weeks), while 48.7% of patients…
April 20, 2026

Read more

Load more